INmune Bio Inc. Common stock INMB
i
Market datapartial · fetched 2026-11-12T01:23:53.220Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:15:20.69266257Z
FundamentalsAlpha Vantage · unavailable
INmune Bio Inc. Common stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 1.87 | 286.9% | 68.9% | |||
| 25Δ | 1.79 | 302.9% | 64.1% | 1.00 | 703.9% | 45.6% |
| 30Δ | 1.70 | 318.9% | 59.2% | 1.10 | 670.6% | 41.7% |
| 35Δ | 1.62 | 335.0% | 54.4% | 1.20 | 637.2% | 37.8% |
| 40Δ | 1.53 | 351.0% | 49.5% | 1.30 | 603.8% | 33.9% |
| 45Δ | 1.44 | 367.0% | 44.7% | 1.40 | 570.4% | 29.9% |
| 50Δ | 1.36 | 383.0% | 39.8% | 1.50 | 537.0% | 26.0% |
| 55Δ | 1.27 | 399.0% | 35.0% | 1.60 | 503.6% | 22.1% |
| 60Δ | 1.19 | 415.0% | 30.1% | 1.70 | 470.3% | 18.1% |
| 65Δ | 1.10 | 431.0% | 25.3% | 1.80 | 436.9% | 14.2% |
| 70Δ | 1.02 | 447.0% | 20.5% | 1.90 | 403.5% | 10.3% |
| 75Δ | 2.02 | 373.8% | 6.5% | |||
| 80Δ | 2.59 | 423.8% | 5.2% | |||
20Δ
- Pseudo strike
- 1.87
- IV
- 286.9%
- B/E move
- 68.9%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 1.79
- IV
- 302.9%
- B/E move
- 64.1%
- Pseudo strike
- 1.00
- IV
- 703.9%
- B/E move
- 45.6%
30Δ
- Pseudo strike
- 1.70
- IV
- 318.9%
- B/E move
- 59.2%
- Pseudo strike
- 1.10
- IV
- 670.6%
- B/E move
- 41.7%
35Δ
- Pseudo strike
- 1.62
- IV
- 335.0%
- B/E move
- 54.4%
- Pseudo strike
- 1.20
- IV
- 637.2%
- B/E move
- 37.8%
40Δ
- Pseudo strike
- 1.53
- IV
- 351.0%
- B/E move
- 49.5%
- Pseudo strike
- 1.30
- IV
- 603.8%
- B/E move
- 33.9%
45Δ
- Pseudo strike
- 1.44
- IV
- 367.0%
- B/E move
- 44.7%
- Pseudo strike
- 1.40
- IV
- 570.4%
- B/E move
- 29.9%
50Δ
- Pseudo strike
- 1.36
- IV
- 383.0%
- B/E move
- 39.8%
- Pseudo strike
- 1.50
- IV
- 537.0%
- B/E move
- 26.0%
55Δ
- Pseudo strike
- 1.27
- IV
- 399.0%
- B/E move
- 35.0%
- Pseudo strike
- 1.60
- IV
- 503.6%
- B/E move
- 22.1%
60Δ
- Pseudo strike
- 1.19
- IV
- 415.0%
- B/E move
- 30.1%
- Pseudo strike
- 1.70
- IV
- 470.3%
- B/E move
- 18.1%
65Δ
- Pseudo strike
- 1.10
- IV
- 431.0%
- B/E move
- 25.3%
- Pseudo strike
- 1.80
- IV
- 436.9%
- B/E move
- 14.2%
70Δ
- Pseudo strike
- 1.02
- IV
- 447.0%
- B/E move
- 20.5%
- Pseudo strike
- 1.90
- IV
- 403.5%
- B/E move
- 10.3%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.02
- IV
- 373.8%
- B/E move
- 6.5%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.59
- IV
- 423.8%
- B/E move
- 5.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 243.13% | |
| 185.80% | |
| 202.95% | |
| 165.64% | |
| 233.62% | |
| 313.00% |
Biotechnology
INO
Description unavailable
More →INSM
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New…
More →INVA
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
More →IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
More →IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's…
More →IPSC
Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy, with a transformative approach to cancer treatment. Leveraging…
More →